English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Horizon Therapeutics
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily
| May 7, 2023
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily
| Apr 24, 2023
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Patient Daily
| Apr 24, 2023
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Patient Daily
| Apr 24, 2023
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Trending
+
Pharmaceuticals
Patient Daily
| Jun 2, 2025
PathAI collaborates with Northwestern Medicine on digital pathology advancements
+
Regulatory
Patient Daily
| May 30, 2025
Alliance for Pharmacy Compounding calls for eliminating redundant, unauthorized, or ineffective regulation
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
Exon 20 Group questions effectiveness of 340B drug program
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
New study identifies indicators for HER2+ breast cancer therapy response
